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Trimethoprim crystallizes in the triclinic space group P-1 (#2) with a = 10.5085(3), b = 10.5417(2),
c = 8.05869(13) Å, α = 101.23371(21), β = 112.1787(3), γ = 112.6321(4)°, V = 743.729 Å3, and Z = 2.
A reduced cell search in the Cambridge Structural Database yielded three previous structure
determinations, using data collected at 100 K, 173 K, and room temperature. In this work, the sample
was ordered from the United States Pharmacopeial Convention (USP) and analyzed as-received.
The room temperature (295 K) crystal structure was refined using synchrotron (λ = 0.412826 Å)
powder diffraction data and optimized using density functional theory techniques. We found similar
hydrogen bonding patterns with the previous determinations. In addition, we identified two C–H⋯O
hydrogen bonds, which also contribute to the crystal energy. When comparing the previously
reported trimethoprim structure determinations, the unit cell length lattice parameters were
found to contract at lower temperatures, particularly 100 K. All structures show reasonable agreement,
with unit cell length differences ranging between 0.05 and 0.15 Å. The diffraction data for this
study were collected on beamline 11-BM at the Advanced Photon Source, and the powder X-ray
diffraction pattern of the compound has been submitted to ICDD® for inclusion in the Powder
Diffraction File™ (PDF®). © 2020 International Centre for Diffraction Data.
[doi:10.1017/S0885715619000927]
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Trimethoprim (Primsol) is an antibiotic used primarily to treat
bladder infections. Other uses include treating middle ear
infections and traveler’s diarrhea. Commercial trimethoprim,
CAS #738-70-5, crystallizes in the triclinic space group P-1
(#2) with a = 10.5085(3), b = 11.2000(2), c = 8.05869(13) Å,
α = 101.2337(2), β = 112.1787(3), γ = 112.6321(4)°, V =
743.729(3) Å3, and Z = 2. A reduced cell search in the
Cambridge Structural Database (Groom et al., 2016) yielded
three previous structure determinations, using X-ray data col-
lected at 100 K (Maddileti et al., 2015), 173 K (Rauf and
Bolte, 2006), and neutron data assumed to be collected at
room temperature (Koetzle and Williams, 1976; Figure 1).
In this work, the sample was ordered from the United
States Pharmacopeial Convention (USP) (Lot #L0M053)
and analyzed as-received. The diffraction data for this study
were collected on beamline 11-BM at the Advanced Photon
Source, Argonne National Laboratory. The room temperature
(295 K) crystal structure was refined using synchrotron (λ =
0.412826 Å) powder diffraction data and optimized using
density functional theory techniques. Hydrogen positions
were included as a part of the structure and were re-calculated
during the refinement.
We found hydrogen bonding patterns consistent with
the previous determinations. In addition, we identified two
C–H⋯O hydrogen bonds, which also contribute to the crystal
energy. When comparing the previously reported trimetho-
prim structure determinations, the lattice parameters were
found to contract at lower temperatures, particularly 100 K
(Figure 2). All structures show reasonable agreement, with
unit cell differences ranging between 0.05 and 0.15 Å.
These differences will have an effect on diffraction peak posi-
tions and subsequently phase identification at room tempera-
ture, thus the need for high-quality, room temperature X-ray
diffraction data (Kaduk et al., 2014). The powder X-ray dif-
fraction pattern of the compound has been submitted to
ICDD® for inclusion in the Powder Diffraction File™
(PDF®) (Gates and Blanton, 2019; Table I).
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CIF and/or RAW data files were deposited with ICDD.
You may request this data from ICDD at info@icdd.com.
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Figure 1. (Colour online) Powder X-ray diffraction pattern of trimethoprim. The Rietveld-refined structure is indicated in red, and the density functional theory-
optimized structure is indicated in blue.
Figure 2. (Colour online) Lattice parameters of trimethoprim as a function of
the temperature. The curves are intended to guide the eye.
TABLE I. Hydrogen bonds (CRYSTAL14) in trimethoprim.
H-bond D-H (Å) H⋯A (Å) D⋯A (Å) D-H⋯A (°) Overlap (e) E (kcal mol−1)
N2–H1⋯N1 1.025 1.988 3.011 175.3 0.067 a
N2–H5⋯O2 1.011 2.097 2.923 137.4 0.029 3.9
N4–H7⋯N3 1.026 1.988 3.012 175.8 0.070 a
N4–H8⋯O1 1.010 2.448 3.251 136.0 0.018 3.1
C10–H9⋯O3 1.090 2.516 3.587 167.2 0.018 a
C11–H10⋯C8 1.082 2.695b 3.043 98.1 0.013 a
aCorrelation between overlap population and hydrogen bond energy not yet available for C–H⋯O and N–H⋯N hydrogen bonds.
bIntramolecular.
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